These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 36593066)

  • 21. Primary malignant melanoma of the esophagus: differentiation from esophageal squamous cell carcinoma and leiomyoma using dynamic contrast-enhanced CT findings.
    Shi YJ; Yang X; Yan S; Li XT; Wei YY; Zhang XY; Sun YS
    Abdom Radiol (NY); 2022 Aug; 47(8):2747-2759. PubMed ID: 35668195
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Primary malignant melanoma of the esophagus with multiple lymph node metastases: A case report and literature review.
    Iwasaki K; Ota Y; Yamada E; Takahashi K; Watanabe T; Makuuchi Y; Suda T; Osaka Y; Seshimo A; Katsumata K; Tsuchida A
    Medicine (Baltimore); 2020 May; 99(22):e18573. PubMed ID: 32481357
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Primary malignant melanoma of the esophagus: a study of clinical features, pathology, management and prognosis.
    Yu H; Huang XY; Li Y; Xie X; Zhou JL; Zhang LJ; Fu JH; Wang X
    Dis Esophagus; 2011 Feb; 24(2):109-13. PubMed ID: 21040150
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinicopathological characterization of ten patients with primary malignant melanoma of the esophagus and literature review.
    Zhou SL; Zhang LQ; Zhao XK; Wu Y; Liu QY; Li B; Wang JJ; Zhao RJ; Wang XJ; Chen Y; Wang LD; Kong LF
    World J Gastrointest Oncol; 2022 Sep; 14(9):1739-1757. PubMed ID: 36187400
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Characterization of genetics in patients with mucosal melanoma treated with immune checkpoint blockade.
    Buchbinder EI; Weirather JL; Manos M; Quattrochi BJ; Sholl LM; Brennick RC; Bowling P; Bailey N; Magarace L; Ott PA; Haq R; Izar B; Giobbie-Hurder A; Hodi FS
    Cancer Med; 2021 Apr; 10(8):2627-2635. PubMed ID: 33724703
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Primary Malignant Melanoma of the Esophagus With Unusual Endoscopic Findings: A Case Report and Literature Review.
    Liu H; Yan Y; Jiang CM
    Medicine (Baltimore); 2016 Apr; 95(17):e3479. PubMed ID: 27124046
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Primary malignant melanoma of the esophagus: a case report.
    Machado J; Ministro P; Araújo R; Cancela E; Castanheira A; Silva A
    World J Gastroenterol; 2011 Nov; 17(42):4734-8. PubMed ID: 22180718
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical characteristics and treatment outcomes of primary malignant melanoma of esophagus: a single center experience.
    Kim TS; Min BH; Min YW; Lee H; Rhee PL; Kim JJ; Lee JH
    BMC Gastroenterol; 2022 Mar; 22(1):157. PubMed ID: 35351022
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy of PD-1-based immunotherapy after radiologic progression on targeted therapy in stage IV melanoma.
    Kreft S; Gesierich A; Eigentler T; Franklin C; Valpione S; Ugurel S; Utikal J; Haferkamp S; Blank C; Larkin J; Garbe C; Schadendorf D; Lorigan P; Schilling B
    Eur J Cancer; 2019 Jul; 116():207-215. PubMed ID: 31212163
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Primary malignant melanoma of the esophagus with extensive intraepithelial extension.
    Inadomi K; Ishimoto T; Watanabe M; Iwatsuki M; Arima K; Ida S; Nagai Y; Iwagami S; Baba Y; Sakamoto Y; Miyamoto Y; Honda Y; Iyama K; Baba H
    Ann Thorac Surg; 2012 Dec; 94(6):2105-7. PubMed ID: 23176922
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tissue-resident memory T cells from a metastatic vaginal melanoma patient are tumor-responsive T cells and increase after anti-PD-1 treatment.
    Pizzolla A; Keam SP; Vergara IA; Caramia F; Thio N; Wang M; Kocovski N; Tantalo D; Jabbari J; Au-Yeung G; Sandhu S; Gyorki DE; Weppler A; Perdicchio M; McArthur GA; Papenfuss AT; Neeson PJ
    J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35550554
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Primary malignant melanoma of the esophagus: A case report.
    Wang QQ; Li YM; Qin G; Liu F; Xu YY
    World J Clin Cases; 2023 Feb; 11(6):1426-1433. PubMed ID: 36926119
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Single-cell transcriptome analysis reveals TOX as a promoting factor for T cell exhaustion and a predictor for anti-PD-1 responses in human cancer.
    Kim K; Park S; Park SY; Kim G; Park SM; Cho JW; Kim DH; Park YM; Koh YW; Kim HR; Ha SJ; Lee I
    Genome Med; 2020 Feb; 12(1):22. PubMed ID: 32111241
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Predominance of triple wild-type and IGF2R mutations in mucosal melanomas.
    Iida Y; Salomon MP; Hata K; Tran K; Ohe S; Griffiths CF; Hsu SC; Nelson N; Hoon DSB
    BMC Cancer; 2018 Oct; 18(1):1054. PubMed ID: 30373548
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intratumoral CD73: An immune checkpoint shaping an inhibitory tumor microenvironment and implicating poor prognosis in Chinese melanoma cohorts.
    Gao Z; Wang L; Song Z; Ren M; Yang Y; Li J; Shen K; Li Y; Ding Y; Yang Y; Zhou Y; Wei C; Gu J
    Front Immunol; 2022; 13():954039. PubMed ID: 36131912
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment outcome of PD-1 immune checkpoint inhibitor in Asian metastatic melanoma patients: correlative analysis with PD-L1 immunohistochemistry.
    Cho J; Ahn S; Yoo KH; Kim JH; Choi SH; Jang KT; Lee J
    Invest New Drugs; 2016 Dec; 34(6):677-684. PubMed ID: 27491654
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Radiological dynamics and SITC-defined resistance types of advanced melanoma during anti-PD-1 monotherapy: an independent single-blind observational study on an international cohort.
    Bai X; Kim M; Kasumova G; Si L; Tang B; Cui C; Yang X; Wei X; Cohen J; Lawrence D; Freedman C; Fadden R; Rubin K; Sharova T; Frederick D; Flaherty K; Sullivan R; Guo J; Boland G
    J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33632901
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tumor CD155 Expression Is Associated with Resistance to Anti-PD1 Immunotherapy in Metastatic Melanoma.
    Lepletier A; Madore J; O'Donnell JS; Johnston RL; Li XY; McDonald E; Ahern E; Kuchel A; Eastgate M; Pearson SA; Mallardo D; Ascierto PA; Massi D; Merelli B; Mandala M; Wilmott JS; Menzies AM; Leduc C; Stagg J; Routy B; Long GV; Scolyer RA; Bald T; Waddell N; Dougall WC; Teng MWL; Smyth MJ
    Clin Cancer Res; 2020 Jul; 26(14):3671-3681. PubMed ID: 32345648
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Baseline β-catenin, programmed death-ligand 1 expression and tumour-infiltrating lymphocytes predict response and poor prognosis in BRAF inhibitor-treated melanoma patients.
    Massi D; Romano E; Rulli E; Merelli B; Nassini R; De Logu F; Bieche I; Baroni G; Cattaneo L; Xue G; Mandalà M
    Eur J Cancer; 2017 Jun; 78():70-81. PubMed ID: 28412591
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of radiotherapy and sequencing of systemic therapy on survival outcomes in melanoma patients with previously untreated brain metastasis: a multicenter DeCOG study on 450 patients from the prospective skin cancer registry ADOREG.
    Franklin C; Mohr P; Bluhm L; Grimmelmann I; Gutzmer R; Meier F; Garzarolli M; Weichenthal M; Pfoehler C; Herbst R; Terheyden P; Utikal J; Ulrich J; Debus D; Haferkamp S; Kaatz M; Forschner A; Leiter U; Nashan D; Kreuter A; Sachse M; Welzel J; Heinzerling L; Meiss F; Weishaupt C; Gambichler T; Weyandt G; Dippel E; Schatton K; Celik E; Trommer M; Helfrich I; Roesch A; Zimmer L; Livingstone E; Schadendorf D; Horn S; Ugurel S
    J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35688555
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.